SCENARIA View Phase 6.0
Fujifilm Corporation · Decision date Sep 18, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on September 18, 2026 for SCENARIA View Phase 6.0, submitted by Fujifilm Corporation under 510(k) number K261229. The application was received April 15, 2026, reviewed under regulation 892.1750 in the Radiology panel, with classification product code JAK for computed tomography X-ray systems. A SESE decision is a 510(k) clearance, not a premarket approval.
The reviewed material describes DLR Focus, a deep-learning-based noise-reduction component using convolutional processing from a trained model. The available conclusion states that phantom and clinical image testing showed noise reduction without image quality degradation relative to the conventional method. The source does not specify which system components or labeling changed in Phase 6.0, the full indications, or the detailed test results; those remain in the underlying FDA documents rather than this summary.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Radiology
- Decision date
- Sep 18, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K261229
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Fujifilm Corporation
- Product code
- JAK
- Decision code
- SESE
- Decision date
- Sep 18, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: System, X-Ray, Tomography, Computed.
- Applicant
- Fujifilm Corporation
- Product code
- JAK
- FDA device class
- 2
FDA decision timeline
K261229 received
Application receipt date recorded by FDA.
K261229 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code JAK
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
AVIEW Aorta MetricsK260391 | Coreline Soft Co., Ltd. | 510(k) clearance | Oct 16, 2026 | FDA |
CAS-One IRK261225 | Cascination AG | 510(k) clearance | Sep 29, 2026 | FDA |
| Samsung HME America, Inc., dba NeuroLogica Corp. | 510(k) clearance | Sep 22, 2026 | FDA | |
FCT iStream Phase 2K253836 | Fujifilm Corporation | 510(k) clearance | Sep 4, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Fujifilm Corporation
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Minato-Ku
Sources and methodology
- Original FDA record: K261229
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

